Background We have previously reported that intramuscular, intradermal or epidermal gene gun administration of a plasmid encoding carcinoembryonic antigen (CEA) under transcriptional regulatory control of the cytomegalovirus (CMV) early promoter/enhancer elicits CEA-speci®c humoral and cellular immu
Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6
✍ Scribed by Ryo Ueda; Eiko Kinoshita; Rena Ito; Takeshi Kawase; Yutaka Kawakami; Masahiro Toda
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- French
- Weight
- 219 KB
- Volume
- 122
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We previously reported identifying SOX6 as a glioma antigen by serological screening using a testis cDNA library. Its preferential expression and frequent IgG responses in glioma patients indicate that SOX6 may be a useful target for immunotherapy. To examine whether cytotoxic T‐lymphocyte (CTL) responses specific for SOX6 to destroy glioma can be generated in vivo, we treated glioma‐bearing mice by vaccination with a plasmid DNA encoding murine full‐length SOX6 protein. Following SOX6‐DNA vaccination, CTLs specific for SOX6‐expressing glioma cells were induced, while normal autologous‐cells that had restrictedly expressed SOX6 during embryogenesis were not destroyed. Furthermore, DNA vaccination with SOX6 exerted protective and therapeutic antitumor responses in the glioma‐bearing mice. This antitumor activity was abrogated by the depletion of CD4 positive T cells and/or CD8 positive T cells. These results suggest that the SOX6 protein has multiple CTL and helper epitopes to induce antitumor activity and the effectiveness of SOX6‐DNA vaccine for the prevention and treatment of glioma. © 2008 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract The identification of a safe and effective adjuvant that is able to enhance mucosal immune responses is necessary for the development of an efficient inactivated intranasal influenza vaccine. The present study demonstrated the effectiveness of extracts of mycelia derived from edible mus
CTLs specific for tumor antigens play a major role in immunity against cancer. Improved binding affinity of putative TAA peptides could enhance the in vivo immunogenicity of these self-altered self-tumor antigens. We examined here the efficacy of tumor vaccines composed of an altered peptide ligand